Howland Capital Management LLC Decreases Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Howland Capital Management LLC decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 1.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 76,956 shares of the company’s stock after selling 1,222 shares during the period. Howland Capital Management LLC’s holdings in Kenvue were worth $1,643,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KVUE. AMF Tjanstepension AB increased its position in shares of Kenvue by 187.3% during the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after purchasing an additional 78,540 shares during the last quarter. Mather Group LLC. increased its position in shares of Kenvue by 62.0% during the 3rd quarter. Mather Group LLC. now owns 6,857 shares of the company’s stock valued at $159,000 after purchasing an additional 2,625 shares during the last quarter. Atomi Financial Group Inc. purchased a new stake in shares of Kenvue during the 3rd quarter valued at about $212,000. Perpetual Ltd increased its position in shares of Kenvue by 2.6% during the 3rd quarter. Perpetual Ltd now owns 25,380 shares of the company’s stock valued at $587,000 after purchasing an additional 652 shares during the last quarter. Finally, Juncture Wealth Strategies LLC purchased a new stake in shares of Kenvue during the 3rd quarter valued at about $241,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on KVUE shares. Citigroup reduced their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Bank of America increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, Barclays reduced their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Stock Up 2.2 %

NYSE KVUE opened at $20.23 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $38.79 billion, a P/E ratio of 38.17, a P/E/G ratio of 2.16 and a beta of 1.45. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The stock has a 50 day moving average price of $21.54 and a 200-day moving average price of $21.95.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts predict that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.05%. Kenvue’s dividend payout ratio is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.